dydrogesterone / Generic mfg. - LARVOL DELTA

Efficacy of Daily 50 mg Intramuscular Progesterone for Luteal Phase Support in Frozen Embryo Transfer Cycles: Analysis of Serum Levels and Pregnancy Outcomes. (PubMed, J Family Reprod Health) - "Endometrial preparation began with oral estradiol valerate (6 mg/day) on cycle day 2...Serum P4 levels were measured on ET day, and oral dydrogesterone (20 mg/day) was added for patients with P4 levels 27.8 ng/mL) were associated with reduced chemical pregnancy rates, the absence of significant correlations with other pregnancy outcomes highlights the multifactorial nature of embryo implantation success. These findings emphasize the need for further research to refine P4 thresholds and identify additional predictive factors influencing pregnancy outcomes in FET cycles."

Journal

Successful Pregnancy Outcome in a Patient with Recurrent Miscarriage Due to PCOS Complicated by Hereditary Protein C Deficiency. (PubMed, Int J Womens Health) - "Our regimen comprises dydrogesterone for cycle regulation, rivaroxaban for PC deficiency-related thrombophilia, and metformin, amoxicillin, and omeprazole to manage PCOS-associated insulin resistance and chronic endometritis, with the aim of mitigating their contribution to impaired endometrial receptivity. Multi-disciplinary treatment (MDT) is crucial. Moreover, there are currently no international, evidence-based guidelines for the use of combined oral contraceptives (COCs) in PCOS complicated by hereditary thrombophilia, highlighting the urgent need for multicenter clinical studies to establish appropriate management strategies."

Journal • Cardiovascular • Endometriosis • Hematological Disorders • Pain • Polycystic Ovary Syndrome • Thrombosis • Venous Thromboembolism

Congenital anomalies after first-trimester dydrogesterone therapy during in vitro fertilization. (PubMed, Reprod Biol Endocrinol) - No abstract available

Journal • Preclinical • Gynecology

Uterine artery S/D ratio and serum CA125 as predictors of early pregnancy loss in women with ovarian endometriomas: a retrospective case-control study. (PubMed, BMC Pregnancy Childbirth) - "Elevated serum CA125 levels and increased uterine artery S/D ratio are independently associated with increased risk of early spontaneous miscarriage in women with endometriosis with ovarian endometriomas smaller than 4 cm who conceive naturally. The combined assessment of CA125 levels and uterine artery S/D ratio during early pregnancy provides useful risk stratification for identifying high-risk patients, potentially enabling targeted interventions to improve pregnancy outcomes in these women."

Journal • Retrospective data • Endometriosis • Gynecology • Infertility • Sexual Disorders • Women's Health • MUC16

Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Ege University

New trial • Polycystic Ovary Syndrome

Impact of Follicle Size at Trigger on Reproductive Outcomes in Letrozole-Modified Natural Frozen Embryo Transfer Cycles in High Responder Patients. (PubMed, J Assist Reprod Genet) - "Although OPR did not differ across follicle-size strata, larger follicle size at trigger and higher endogenous luteal P4 were independent predictors of OPR in highresponders. Confirmation in adequately powered prospective studies is warranted."

Journal

Age-stratified analysis of euploidy rates in Progestin-Primed Ovarian Stimulation (PPOS) utilizing micronized progesterone or dydrogesterone versus GnRH analogues. (PubMed, J Ovarian Res) - "PPOS protocols using micronized progesterone or dydrogesterone were statistically comparable with conventional COS regimens in euploidy rates across all different age groups. Considering the significant impact of age, the necessity of refined age stratification for a more rigorous discussion about the aneuploidy risk of different COS protocols was emphasized."

Journal

Evaluation of the long-term efficacy and safety of dydrogesterone in the treatment of endometriosis/dysmenorrhea. (PubMed, BMC Womens Health) - "Dydrogesterone can effectively control endometriotic lesions in most women and significantly improve dysmenorrhea and quality of life."

Journal • Endometriosis • Gynecology • Pain • Women's Health

Live birth rates are unrelated to sex-steroid levels on ET day in a dydrogesterone-based 'programmed-ovulatory FET' protocol: a multi-centric prospective cohort study. (PubMed, Hum Reprod Open) - P | "We propose the term 'Programmed-Ovulatory (PO-) FET' for this protocol. The PO-FET protocol enables scheduling the window of implantation, allows ovulation and corpus luteum formation, provides double gestagenic support, and may eliminate the need for control measurements of sex steroids on the day of FET. It allows monitoring of corpus luteum activity during the luteal phase and early pregnancy, is injection-free, and has low drug costs. This protocol needs to be tested in RCTs against other ovulatory FET protocol options, such as the 'NC FET' or 'managed NC FET'."

Journal • Endocrine Disorders

ORAL DYDROGESTERONE VS. MICRONIZED VAGINAL PROGESTERONE FOR LUTEAL SUPPORT IN ARTIFICIAL FROZEN EMBRYO TRANSFER CYCLES: A RANDOMIZED CONTROLLED TRIAL (ASRM 2025) - No abstract available

Clinical

Carboxyl-PEG modified Fe3O4 nanoparticles as an ultrasensitive SERS substrate for multiplex detection of exogenous hormones related to endometrial cancer. (PubMed, Methods) - "This approach successfully enabled ultrasensitive detection and precise discrimination of multiple typical exogenous hormonal drugs, including tamoxifen, drospirenone, cyproterone acetate, medroxyprogesterone acetate, estradiol ester derivatives, and dydrogesterone. In matrix-spiked serum and urine samples, which mimic complex biological matrices validations, the AI-SERS platform demonstrated exceptional performance in the identification and quantitative analysis of target exogenous hormones. This research provides an intelligent analytical strategy for rapid and highly sensitive detection of multiple trace exogenous hormones in complex matrices."

Journal • Endometrial Cancer • Oncology • Solid Tumor

A prospective, randomized controlled trial of progestogens for luteal-phase support in IVF-ET (ChiCTR) - P4 | N=290 | Not yet recruiting | Sponsor: Sichuan Provincial Women and Children's Hospital; Sichuan Provincial Women and Children's Hospital

New P4 trial • Infertility • Sexual Disorders

Retrospective cohort study and meta-analysis of individualized luteal phase support with additional oral dydrogesterone in artificially prepared frozen embryo transfer cycles. (PubMed, J Assist Reprod Genet) - "Individualized luteal phase support with DYD supplementation in patients with low luteal serum P4 levels during an HRT cycle for FET achieves LBR comparable to those observed in patients with adequate serum P4 levels, both in this cohort study and in a complementary meta-analysis."

Journal • Retrospective data

Relationship between MASLD and women's health: A review. (PubMed, Womens Health (Lond)) - "However, transdermal estrogen and micronized progesterone or dydrogesterone seem to be more appropriate options. It may also increase the risk of MASLD development in the offspring-an effect that appears to be mitigated by breastfeeding for longer than six months. Given these findings, it is essential that clinicians involved in women's healthcare are aware of MASLD and its implications across the female lifespan."

Journal • Review • Addiction (Opioid and Alcohol) • Diabetes • Fibrosis • Genetic Disorders • Gestational Diabetes • Gynecology • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Oncology • Polycystic Ovary Syndrome • Solid Tumor • Transplantation • Type 2 Diabetes Mellitus • Women's Health

Sequential therapy for infertility in women with polycystic ovary syndrome and luteal phase defects by Yangxin Dianji decoction and Nuangong Tiaojing decoction: a real-world study. (PubMed, J Tradit Chin Med) - "The sequential therapy of YXDJ-D and NGTJ-D can effectively increase pregnancy rate, reduce the early abortion rate and alleviate the clinical symptoms of infertility in patients with PCOS and LPD by improving luteal function and promoting the endometrial receptivity."

Journal • Real-world evidence • Infertility • Polycystic Ovary Syndrome • Sexual Disorders

Efficacy of Oral Dydrogesterone in Improving Neonatal Birth Weight Outcomes in Idiopathic Intrauterine Growth Restriction: A Prospective Observational Study. (PubMed, Cureus) - "Progesterone analogues have emerged as potential therapeutic agents for managing pregnancy-related complications, though evidence regarding their specific application in idiopathic IUGR remains limited. Conclusion Oral dydrogesterone supplementation demonstrates significant therapeutic efficacy in improving neonatal birth weight outcomes in idiopathic IUGR with an excellent safety profile. The substantial birth weight improvement of 0.50 kg supports potential integration into evidence-based clinical protocols for this challenging obstetric condition, warranting further large-scale randomized controlled trials for definitive clinical validation."

Journal • Observational data • Gynecology • Obstetrics

First-Trimester Uterine Artery Doppler Indices and Pregnancy Outcomes in Naturally Conceived and Frozen-Thawed Embryo Transfer Cycles. (PubMed, Diagnostics (Basel)) - " This retrospective cohort study included 289 singleton pregnancies comprising spontaneous conceptions, FET cycles supported with oral micronised progesterone, and FET cycles supported with oral dydrogesterone. Dydrogesterone was associated with more favorable uterine artery Doppler indices in early pregnancy, suggesting improved uteroplacental adaptation in FET cycles. These findings support further prospective research to determine the clinical impact of LPS regimens on placental development and perinatal health."

Journal • Diabetes • Gestational Diabetes • Metabolic Disorders

A retrospective comparison of live birth rate in freeze-all cycles between progestin-primed ovarian stimulation with dydrogesterone and GnRH antagonist protocols. (PubMed, Eur J Obstet Gynecol Reprod Biol) - "The PPOS-dydrogesterone protocol has a similar live birth rate to the GnRH antagonist protocol in IVF freeze-all cycles, with added benefits in blastocyst yield despite higher stimulation demands. Patient factors, rather than protocol choice, primarily drive outcomes, positioning the PPOS-dydrogesterone protocol as an effective alternative to the GnRH antagonist protocol."

Journal • Retrospective data • Gynecology

Comment on "Fewer good-quality cleavage embryos in dydrogesterone-primed ovarian stimulation compared to GnRH antagonist protocol in POSEIDON group 4 patients": Fewer good-quality cleavage embryos in dydrogesterone-primed ovarian stimulation. (PubMed, J Formos Med Assoc) - No abstract available

Journal

Progestogen therapy in threatened miscarriage and unexplained recurrent pregnancy loss: Recommendations by the Thai interest group. (PubMed, J Obstet Gynaecol Res) - "These inaugural evidence-based Thai recommendations can be applied in regional healthcare settings for improved outcomes in threatened miscarriage and unexplained RPL. Further research is needed to better understand the epidemiology and etiology of these conditions in Thailand."

Journal • Review

Pregnancy and perinatal outcomes after modified natural cycle-frozen embryo transfers according to size of the dominant follicle on the hCG trigger day. (PubMed, Hum Reprod Open) - "The current data suggest that with the administration of an intensive LPS, the hCG trigger can be given across a wide range of follicle sizes, from above 10 to 18 mm or larger in diameter, in modified NC-FETs. This approach not only simplifies patient monitoring but also offers greater flexibility and autonomy in scheduling the date of embryo transfer."

Journal • Obstetrics

Comparison of oral dydrogesterone and vaginal progesterone for luteal phase support in natural and modified natural cycle frozen embryo transfers. (PubMed, J Ovarian Res) - "In NC-FET cycles, oral DYD demonstrates clinical efficacy comparable to MVP and combined medication. As a monotherapy, oral DYD expands therapeutic options, offering a convenient and effective choice to improve adherence and achieve similar pregnancy outcomes. This finding is significant for guiding clinical practices towards optimal treatment strategies that prioritize patient compliance and satisfaction."

Journal

Exploring the Inhibitory Effects of Guben Antai Decoction on Oxidative Stress Damage and Ferroptosis via the Nrf2/HO-1 Pathway: A Mechanistic Study on Improving Recurrent Spontaneous Abortion. (PubMed, J Ethnopharmacol) - "This study is the first to demonstrate that GBAT mitigates ferroptosis in trophoblasts by activating the Nrf2/HO-1 pathway, providing new mechanistic insights into its potential for treating RSA."

Journal • ACSL4 • GPX4 • SLC7A11

Comparison of the effect of combination of alprosterone and dydrogesterone on luteal support after fresh cycle transplantation (ChiCTR) - P=N/A | N=216 | Not yet recruiting | Sponsor: The Second Affiliated Hospital Of Zhengzhou University; The Second Affiliated Hospital Of Zhengzhou University

New trial • Infertility • Sexual Disorders • Transplantation

RETRACTION: Comparison of the Effect of Dydrogesterone and Natural Micronized Progesterone for Luteal-Phase Support in Assisted Reproductive Technology Cycles: A Single-Blind Randomized Clinical Trial Study. (PubMed, Health Sci Rep) - "[This retracts the article DOI: 10.1002/hsr2.2296.]."

Clinical • Journal